Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PICSTAT: CD8 PET/CT to Enhance Lifileucel in Melanoma
NCT07700121Phase 1Not yet recruiting
- Sponsor
- Abramson Cancer Center
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lifileucel and zirconium-89 crefmirlimab berdoxam in melanoma, sponsored by Abramson Cancer Center. Primary endpoint: Tumor-Infiltrating Lymphocytes. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
lifileucelzirconium-89 crefmirlimab berdoxam
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07700121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07700121.